查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1401940

2030 年血浆分馏市场预测：按产品、方法、应用、最终用户和地区进行的全球分析

Plasma Fractionation Market Forecasts to 2030 - Global Analysis By Product (Immunoglobulins, Albumin, Platelets & Coagulation Factor Concentrates, Protease Inhibitors and Other Products), Method, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球血浆分馏市场规模将达到 290 亿美元，预计到 2030 年将达到 462 亿美元，预测期内复合年增长率为 6.9%。

为了创造可用于治疗各种医疗状况的治疗产品，血浆的组成部分透过称为血浆分馏的过程进行分离。血液的液体部分称为血浆，含有蛋白质和身体运作所需的其他物质。血浆分馏分离和精製这些蛋白质用于医疗用途。血浆分馏是一种重要的手术，可为多种疾病提供挽救生命的治疗方法。然而，必须严格遵守品质和安全要求，以确保成品无害、高效、无杂质。

根据 Springer 2022 年 1 月发表的一项研究，获得性A型血友病(AHA) 是一种罕见、严重的后天性出血性疾病，每年每百万人中仅影响 1 至 150 人。

免疫不全症增加

在全球范围内，对血浆生产的治疗药物的需求显着增加。对免疫球蛋白的强劲需求促进了全球市场的强劲扩张。需求的增加是由于全球各种免疫力缺乏疾病的增加。免疫球蛋白替代疗法或标靶免疫球蛋白疗法是这些疾病的两种可能的治疗方法。因此，随着对这些治疗方法的需求增加，透过这些方法产生的免疫球蛋白的量也增加，从而推动市场。

基因编辑疗法的出现

透过特异性针对基因缺陷，基因编辑疗法提供了疾病治疗的新方法，并可能最终消除对血浆衍生疗法的需求。由于对血浆生产的产品的需求减少，基因编辑疗法的使用可能会导致血浆分馏公司的市场占有率和收入下降。如果治疗模式显着转向基因编辑，严重依赖血浆衍生疗法的公司可能会受到财务影响，从而抑制市场。

世界各地有更多血浆采集设施

血浆（血浆血浆分馏的原料）供应的增加可能会导致收集设施的增加。血浆可用性的增加可能对生产血浆衍生产品（如白蛋白、凝血因子和免疫球蛋白）的能力产生有益影响。血浆分馏市场可能受到血浆采集设施的位置和法律体制的影响。此外，各国关于安全要求、血浆采集以及血浆衍生产品进出口的规定也各不相同。

技术挑战

过时或低效的血浆分馏方法等技术问题可能会增加处理时间并降低生产率。这些低效率可能导致血浆衍生产品的产量降低，限制了可分配的数量并增加了成本。一些过时的技术和流程可能会造成可扩展性问题，从而难以提高生产水准以满足需求。可扩展性不足可能会阻碍市场成长并导致供不应求。

COVID-19 的影响

由于 COVID-19，对血浆产品（尤其是免疫球蛋白）的需求激增。对于严重COVID-19 患者，这些抗体被认为是一种治疗选择。因此，对来自 COVID-19 倖存者的血浆的需求不断增加，以製造恢復期血浆和含有超免疫球蛋白的治疗方法。为了应对大流行带来的挑战，监管机构改变了规则和法规，以确保血浆衍生产品的安全性和可得性。

免疫球蛋白部分预计将成为预测期内最大的部分

由于免疫球蛋白用于治疗各种疾病，如免疫力缺乏、自体免疫疾病和一些神经系统疾病，预计免疫球蛋白领域将出现良好的增长。静脉注射免疫球蛋白（IVIG）是从血浆分馏中获得的物质，广泛用于治疗各种疾病和增强免疫系统。透过血浆分馏程序的持续技术改进，提高了产品产量和质量，从而增强了分离免疫球蛋白和其他血浆蛋白的有效性。

深层过滤领域预计在预测期内复合年增长率最高

由于深度过滤是免疫球蛋白和其他重要成分等蛋白质精製和分离的关键步骤，因此预计深度过滤领域在预测期内将以最高复合年增长率增长。深度过滤是去除污染物、获得高纯度蛋白质产品的关键技术之一。这个过程取决于过滤基质的深度，因为它捕获并保留不同尺寸的颗粒，并根据其尺寸、型态以及与过滤材料的相互作用将它们与所需成分分离。

占有率最大的地区：

预计亚太地区在预测期内将占据最大的市场占有率。这是因为政府当局监督和控制血浆收集、分离和销售是推动市场成长的关键因素，因此，亚太地区是血浆分馏产业的重要参与企业，提供了有利的可能性。此外，专注于开拓亚太地区新兴市场以获取更大市场占有率的顶级製造商的激增预计将推动血浆分馏行业的成长。

复合年增长率最高的地区：

预计北美在预测期内的复合年增长率最高，并且由于主要企业的存在、血浆分馏人口高龄化，预计将占据血浆分馏市场的很大一部分。此外，该地区血浆采集设施的扩建以及提高血浆供应量的持续努力预计将推动市场扩张。例如，Grifols SA 和加拿大血液服务中心 (CBS) 于 2022 年 9 月加入，以增加加拿大的全国血浆供应。因此，老年人口的增加、医疗保健支出的增加以及关键市场的倡议不断增加正在推动市场成长。

免费客製化服务：

订阅此报告的客户可以利用以下免费自订选项之一：

  • 公司简介
    • 其他市场参与企业的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计/预测/复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 介绍
  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球血浆分馏市场：副产品

  • 介绍
  • 免疫球蛋白
    • 皮下注射免疫球蛋白
    • 静脉注射免疫球蛋白
  • 白蛋白
  • 血小板和凝血因子浓缩物
    • 因子VIII
    • 因子IX
    • 血管性血友病因子
    • 纤维蛋白原浓缩物
    • 凝血酶原复合物浓缩物
    • 因子XIII
    • 其他浓缩血小板和凝血因子
  • 蛋白酶抑制剂
  • 其他产品

第六章全球血浆分馏市场：依方法

  • 介绍
  • 深层过滤
  • 层析法
  • 离心

第七章全球血浆分馏市场：依应用分类

  • 介绍
  • 免疫学
  • 神经病学
  • 重症监护
  • 血液学
  • 风湿病学
  • 血液肿瘤学
  • 呼吸系统医疗设备
  • 其他用途

第八章全球血浆分馏市场：依最终用户分类

  • 介绍
  • 临床研究所
  • 医院和诊所
  • 学术机构
  • 其他最终用户

第九章全球血浆分馏市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 中东和非洲其他地区

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司简介

  • Grifols, SA
  • Intas Pharmaceuticals Ltd.
  • LFB
  • Takeda Pharmaceutical company limited
  • Octapharma AG
  • Sanquin
  • Emergent BioSolutions
  • Shanghai Raas Blood Products Co., Ltd.
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
  • Kamada
  • Centurion Pharma
  • Virchow Biotech Private Limited
  • Fusion Healthcare
  • Hemarus Therapeutics Limited
  • Hualan Bioengineering Co., Ltd.
  • China Biologic Products Holdings Inc.
  • ADMA Biologics
  • CSL
  • Baxter International Inc
  • Bio Products Laboratory
Product Code: SMRC24460

According to Stratistics MRC, the Global Plasma Fractionation Market is accounted for $29.0 billion in 2023 and is expected to reach $46.2 billion by 2030 growing at a CAGR of 6.9% during the forecast period. In order to create therapeutic products that can be utilized to treat a variety of medical diseases, blood plasma's constituent parts are separated through a procedure called plasma fractionation. The liquid portion of blood, known as blood plasma, includes proteins and other materials necessary for body operations. These proteins are separated and purified for use in medicine using plasma fractionation. A vital procedure that offers treatments that can save lives for a variety of illnesses is plasma fractionation. Nonetheless, to guarantee that the finished goods are risk-free, efficient, and devoid of impurities, stringent adherence to quality and safety requirements is necessary.

According to a research study published by Springer in January 2022, Acquired hemophilia A (AHA) is a severe acquired rare bleeding disorder with which only 1-1.5 per million persons are affected yearly.

Market Dynamics:

Driver:

Increasing numbers of immunodeficiency disorders

Worldwide, there has been a noticeable increase in the demand for treatments produced from plasma. Strong demand for immunoglobulin contributed to the global market's good expansion. The increase in different immunodeficiency diseases instances worldwide is the cause of the increased demand. Immunoglobulin replacement or targeted immunoglobulin therapy are two possible treatments for these illnesses. Consequently, as the need for these therapies grows, so does the amount of immunoglobulin produced by these methods, which propels the market.

Restraint:

Emergence of gene-editing therapies

By specifically targeting genetic defects, gene-editing therapies provide novel approaches to treating diseases and may eventually eliminate the need for some plasma-derived therapies. The use of gene-editing therapies may lead to a drop in the market share and income for plasma fractionation companies as a result of a decrease in the demand for products produced from plasma. Businesses that depend significantly on plasma-derived treatments may face financial consequences in the event that treatment paradigms significantly shift in favour of gene editing thereby hampering the market.

Opportunity:

Rise in plasma collection facilities across the globe

An increased supply of plasma as the raw material for plasma fractionation could result from more collection facilities. This increase in plasma availability may have a beneficial effect on the ability to produce products derived from plasma, such as albumin, clotting factors, and immunoglobulins. The market for plasma fractionation may be impacted by the location and legal framework of plasma collection facilities. Moreover, regulations pertaining to safety requirements, plasma collection, and the import and export of goods obtained from plasma vary throughout nations.

Threat:

Technological challenges

Problems with technology, like antiquated or ineffective plasma fractionation methods, can cause processing times to increase and productivity to decrease. Lower yields of plasma-derived products could be the consequence of this inefficiency, which would restrict the amount available for distribution and possibly raise expenses. Scalability issues may arise with some outdated technology or processes, making it challenging to raise output levels to keep up with demand. Inadequate scalability can impede the growth of markets and cause shortages in supplies.

COVID-19 Impact

The demand for goods produced from plasma, especially immunoglobulins, surged as a result of COVID-19. For COVID-19 patients who are extremely sick, these antibodies were investigated as a possible therapy option. As a result, there was an increase in the need for plasma from COVID-19 survivors in order to create convalescent plasma and maybe create treatments involving hyper immune globulin. To handle issues brought on by the pandemic, regulatory bodies modified their rules and regulations, guaranteeing the security and availability of goods obtained from plasma.

The immunoglobulins segment is expected to be the largest during the forecast period

The immunoglobulins segment is estimated to have a lucrative growth, as immunoglobulins are used to treat a range of illnesses, such as immune deficiencies, autoimmune disorders, and several neurological ailments. Intravenous immunoglobulin (IVIG) is a widely used substance that is derived from plasma fractionation and is used to treat a variety of illnesses and strengthen the immune system. The effectiveness of isolating immunoglobulins and other plasma proteins has been enhanced by ongoing technological improvements in plasma fractionation procedures, improving product yields and quality.

The depth filtration segment is expected to have the highest CAGR during the forecast period

The depth filtration segment is anticipated to witness the highest CAGR growth during the forecast period, because depth filtration is a crucial step in the purification and separation of proteins, including immunoglobulins and other vital constituents. It is used as one of the main techniques to get high-purity protein products by eliminating contaminants. In order to capture and hold particles of different sizes and separate them from the required components according to their size, shape, and interaction with the filter material, this procedure depends on the depth of the filter matrix thus boosting the market.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period, owing to the presence of governmental authorities that oversee and control plasma collection, fractionation, and sales is a major element driving the market's growth, and as a result, Asia-Pacific offers important participants in the plasma fractionation industry lucrative potential. Furthermore, a sharp increase in the emphasis of top producers on regional expansion in developing Asia-Pacific nations in order to gain a larger market share is anticipated to propel the growth of the plasma fractionation industry.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to the presence of key companies, growing research and development efforts related to plasma fractionation, and an aging population, the North American region is anticipated to occupy a sizable proportion of the market for plasma fractionation. Furthermore, the expansion of plasma collecting facilities in the area as well as ongoing initiatives to increase the availability of plasma is anticipated to fuel market expansion. For example, in order to increase Canada's national blood plasma supply, Grifols SA and Canadian Blood Services (CBS) joined in September 2022. Thus the growing geriatric population, rising healthcare spending, and rising initiatives from key market are propelling the market growth.

Key players in the market:

Some of the key players profiled in the Plasma Fractionation Market include Grifols, S.A., Intas Pharmaceuticals Ltd., LFB, Takeda Pharmaceutical company limited, Octapharma AG, Sanquin, Emergent BioSolutions, Shanghai Raas Blood Products Co., Ltd., Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., Kamada, Centurion Pharma, Virchow Biotech Private Limited, Fusion Healthcare, Hemarus Therapeutics Limited, Hualan Bioengineering Co., Ltd., China Biologic Products Holdings Inc., ADMA Biologics, CSL, Baxter International Inc and Bio Products Laboratory

Key Developments:

In December 2023, Emergent BioSolutions Announces Initiation of Phase 1 Study Evaluating Its Universal Influenza Vaccine Candidate. This current version of Emergent's universal influenza vaccine candidate contains multiple components intended to induce broad.

In October 2023, Baxter Launches Digital Image Capture Capability for PanOptic Plus Ophthalmoscope, the iExaminer Pro System adds a key technology to routine eye exams, designed.

In July 2023, Kamada Announces Kedrion Exercised its Option for Two-Year Extension of KEDRAB® Distribution Agreement in the U.S. The Company Generated Approximately $16 Million in Revenue from Sales of KEDRAB to Kedrion in 2022 and Anticipates a Significant Increase in 2023

Products Covered:

  • Immunoglobulins
  • Albumin
  • Platelets & Coagulation Factor Concentrates
  • Protease Inhibitors
  • Other Products

Methods Covered:

  • Depth Filtration
  • Chromatography
  • Centrifugation

Applications Covered:

  • Immunology
  • Neurology
  • Critical Care
  • Hematology
  • Rheumatology
  • Hemato-Oncology
  • Pulmonology
  • Other Applications

End Users Covered:

  • Clinical Research Laboratories
  • Hospitals & Clinics
  • Academic Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Plasma Fractionation Market, By Product

  • 5.1 Introduction
  • 5.2 Immunoglobulins
    • 5.2.1 Subcutaneous Immunoglobulin
    • 5.2.2 Intravenous Immunoglobulin
  • 5.3 Albumin
  • 5.4 Platelets & Coagulation Factor Concentrates
    • 5.4.1 Factor VIII
    • 5.4.2 Factor IX
    • 5.4.3 Von Willebrand Factor
    • 5.4.4 Fibrinogen Concentrates
    • 5.4.5 Prothrombin Complex Concentrates
    • 5.4.6 Factor XIII
    • 5.4.7 Other Platelets & Coagulation Factor Concentrates
  • 5.5 Protease Inhibitors
  • 5.6 Other Products

6 Global Plasma Fractionation Market, By Method

  • 6.1 Introduction
  • 6.2 Depth Filtration
  • 6.3 Chromatography
  • 6.4 Centrifugation

7 Global Plasma Fractionation Market, By Application

  • 7.1 Introduction
  • 7.2 Immunology
  • 7.3 Neurology
  • 7.4 Critical Care
  • 7.5 Hematology
  • 7.6 Rheumatology
  • 7.7 Hemato-Oncology
  • 7.8 Pulmonology
  • 7.9 Other Applications

8 Global Plasma Fractionation Market, By End User

  • 8.1 Introduction
  • 8.2 Clinical Research Laboratories
  • 8.3 Hospitals & Clinics
  • 8.4 Academic Institutes
  • 8.5 Other End Users

9 Global Plasma Fractionation Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Grifols, S.A.
  • 11.2 Intas Pharmaceuticals Ltd.
  • 11.3 LFB
  • 11.4 Takeda Pharmaceutical company limited
  • 11.5 Octapharma AG
  • 11.6 Sanquin
  • 11.7 Emergent BioSolutions
  • 11.8 Shanghai Raas Blood Products Co., Ltd.
  • 11.9 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
  • 11.10 Kamada
  • 11.11 Centurion Pharma
  • 11.12 Virchow Biotech Private Limited
  • 11.13 Fusion Healthcare
  • 11.14 Hemarus Therapeutics Limited
  • 11.15 Hualan Bioengineering Co., Ltd.
  • 11.16 China Biologic Products Holdings Inc.
  • 11.17 ADMA Biologics
  • 11.18 CSL
  • 11.19 Baxter International Inc
  • 11.20 Bio Products Laboratory

List of Tables

  • Table 1 Global Plasma Fractionation Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Plasma Fractionation Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Plasma Fractionation Market Outlook, By Immunoglobulins (2021-2030) ($MN)
  • Table 4 Global Plasma Fractionation Market Outlook, By Subcutaneous Immunoglobulin (2021-2030) ($MN)
  • Table 5 Global Plasma Fractionation Market Outlook, By Intravenous Immunoglobulin (2021-2030) ($MN)
  • Table 6 Global Plasma Fractionation Market Outlook, By Albumin (2021-2030) ($MN)
  • Table 7 Global Plasma Fractionation Market Outlook, By Platelets & Coagulation Factor Concentrates (2021-2030) ($MN)
  • Table 8 Global Plasma Fractionation Market Outlook, By Factor VIII (2021-2030) ($MN)
  • Table 9 Global Plasma Fractionation Market Outlook, By Factor IX (2021-2030) ($MN)
  • Table 10 Global Plasma Fractionation Market Outlook, By Von Willebrand Factor (2021-2030) ($MN)
  • Table 11 Global Plasma Fractionation Market Outlook, By Fibrinogen Concentrates (2021-2030) ($MN)
  • Table 12 Global Plasma Fractionation Market Outlook, By Prothrombin Complex Concentrates (2021-2030) ($MN)
  • Table 13 Global Plasma Fractionation Market Outlook, By Factor XIII (2021-2030) ($MN)
  • Table 14 Global Plasma Fractionation Market Outlook, By Other Platelets & Coagulation Factor Concentrates (2021-2030) ($MN)
  • Table 15 Global Plasma Fractionation Market Outlook, By Protease Inhibitors (2021-2030) ($MN)
  • Table 16 Global Plasma Fractionation Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 17 Global Plasma Fractionation Market Outlook, By Method (2021-2030) ($MN)
  • Table 18 Global Plasma Fractionation Market Outlook, By Depth Filtration (2021-2030) ($MN)
  • Table 19 Global Plasma Fractionation Market Outlook, By Chromatography (2021-2030) ($MN)
  • Table 20 Global Plasma Fractionation Market Outlook, By Centrifugation (2021-2030) ($MN)
  • Table 21 Global Plasma Fractionation Market Outlook, By Application (2021-2030) ($MN)
  • Table 22 Global Plasma Fractionation Market Outlook, By Immunology (2021-2030) ($MN)
  • Table 23 Global Plasma Fractionation Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 24 Global Plasma Fractionation Market Outlook, By Critical Care (2021-2030) ($MN)
  • Table 25 Global Plasma Fractionation Market Outlook, By Hematology (2021-2030) ($MN)
  • Table 26 Global Plasma Fractionation Market Outlook, By Rheumatology (2021-2030) ($MN)
  • Table 27 Global Plasma Fractionation Market Outlook, By Hemato-Oncology (2021-2030) ($MN)
  • Table 28 Global Plasma Fractionation Market Outlook, By Pulmonology (2021-2030) ($MN)
  • Table 29 Global Plasma Fractionation Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 30 Global Plasma Fractionation Market Outlook, By End User (2021-2030) ($MN)
  • Table 31 Global Plasma Fractionation Market Outlook, By Clinical Research Laboratories (2021-2030) ($MN)
  • Table 32 Global Plasma Fractionation Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 33 Global Plasma Fractionation Market Outlook, By Academic Institutes (2021-2030) ($MN)
  • Table 34 Global Plasma Fractionation Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.